Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Genmab A/S    GMAB   DK0010272202

GENMAB A/S

(GMAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations
Analyst Recommendations on GENMAB A/S
01/15GENMAB A/S : HC Wainwright Adjusts Genmab A/S' Price Target to $49 from $44, Kee..
MT
01/04GENMAB A/S : RBC Capital Adjusts Genmab A/S' Price Target to $46 From $40, Maint..
MT
2020SVB Leerink Adjusts Genmab's Price Target to $34 from $36, Keeps Market Perfo..
MT
2020HC Wainwright Adjusts Genmab's Price Target to $44 From $45, Keeps at Buy
MT
2020Morgan Stanley Adjusts Genmab's Price Target to $37 From $35, Keeps at Overwe..
MT
2020RBC Capital Adjusts Genmab A/S' Price Target to $40 From $38, Maintains Outpe..
MT
2020HC Wainwright Adjusts Genmab's Price Target to $45 From $42, Reiterates Buy R..
MT
2020GLAXOSMITHKLINE : GSK's blood cancer drug wins European panel thumbs-up
RE
2020GENMAB A/S : GSK's blood cancer drug wins European panel thumbs-up
RE
2020GLAXOSMITHKLINE : FDA panel votes in favor of approving GSK's multiple myeloma d..
RE
2020GENMAB : Darzalex Meets Main Endpoint in Light-Chain Amyloidosis Study
DJ